"Based on results from the phase 2 GEOMETRY mono-1 trial, the European Commission has approved capmatinib for patients with non–small cell lung cancer who have MET exon 14 skipping mutations, and a need for systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
The European Commission has approved capmatinib (Tabrecta) for adults with non–small cell lung cancer (NSCLC) who have a MET exon 14 skipping mutation and need for systemic therapy after prior treatment with immunotherapy and/or platinum-based chemotherapy, according to a press release from Novartis."

Pour en savoir plus, consulter l'article original

Références
1. Novartis received European Commission approval for Tabrecta for the treatment of METex14 skipping advanced non–small cell lung cancer. News Release. Novartis. June 22, 2022. Accessed June 22, 2022. https://bit.ly/3ya8r2V
2. FDA grants accelerated approval to capmatinib for metastatic non–small cell lung cancer. News Release. FDA. May 6, 2020. Accessed June 22, 2022. https://bit.ly/3xJGde4